Indivior Pharmaceuticals Inc Stock News

RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of record of the issued and outstanding Indivior common stock as of October 30, 2026 (the “Special Divide...

Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that ​would create a company with about $2.2 billion ‌in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.

•   Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY •   Record Quarterly Total SUBLOCADE® Net Revenue of $ 253 Million in Q2'26, Up 21% YoY •   Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net Income of $142 Million in Q2'26 •   Record Quarterly Adjusted EBITDA of $ 186 Million in Q2'26, Up 111% YoY •   Repurchased Approximately 4.7 Million Shares in Q2'26 for $175 ...